These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10022540)

  • 41. Tumor reactive T cells get a boost.
    Pardoll DM
    Nat Biotechnol; 2002 Dec; 20(12):1207-8. PubMed ID: 12454671
    [No Abstract]   [Full Text] [Related]  

  • 42. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
    Luo C; Wei J; Han W
    Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activation of T cells via tumor antigen specific chimeric receptors: the role of the intracellular signaling domain.
    Losch FO; Müller R; Mutschler B; Neri D; Natali PG; Reth M; Carsetti R
    Int J Cancer; 2003 Jan; 103(3):399-407. PubMed ID: 12471624
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
    Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
    BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells.
    Hombach A; Schneider C; Sent D; Koch D; Willemsen RA; Diehl V; Kruis W; Bolhuis RL; Pohl C; Abken H
    Int J Cancer; 2000 Oct; 88(1):115-20. PubMed ID: 10962448
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advances in CAR T-cell therapy for chronic lymphocytic leukemia.
    Porter DL
    Clin Adv Hematol Oncol; 2018 Feb; 16(2):118-120. PubMed ID: 29741512
    [No Abstract]   [Full Text] [Related]  

  • 47. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
    Weibo P; Zhaoming Y
    Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is it safer CARs that we need, or safer rules of the road?
    Junghans RP
    Mol Ther; 2010 Oct; 18(10):1742-3. PubMed ID: 20885432
    [No Abstract]   [Full Text] [Related]  

  • 49. CAR-modified T-cell therapy for cancer: an updated review.
    Haji-Fatahaliha M; Hosseini M; Akbarian A; Sadreddini S; Jadidi-Niaragh F; Yousefi M
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1339-49. PubMed ID: 26068778
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.
    Hombach AA; Abken H
    Immunotherapy; 2013 Jul; 5(7):677-81. PubMed ID: 23829616
    [No Abstract]   [Full Text] [Related]  

  • 51. CAR T-cell therapy: opportunities and challenges.
    Zhang W
    Immunotherapy; 2016; 8(3):245-7. PubMed ID: 26860858
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
    Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adoptive antitumor immunotherapy in vitro and in vivo using genetically activated erbB2-specific T cells.
    Wang C; Hu W; Shen L; Dou R; Zhao S; Shan D; Yu K; Huang R; Li H
    J Immunother; 2014 Sep; 37(7):351-9. PubMed ID: 25075564
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents.
    Sharifzadeh Z; Rahbarizadeh F; Shokrgozar MA; Ahmadvand D; Mahboudi F; Jamnani FR; Moghimi SM
    Cancer Lett; 2013 Jul; 334(2):237-44. PubMed ID: 22902507
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.
    Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K
    J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity.
    Liao KW; Chen BM; Liu TB; Tzou SC; Lin YM; Lin KF; Su CI; Roffler SR
    Cancer Gene Ther; 2003 Oct; 10(10):779-90. PubMed ID: 14502231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy.
    Rubin CB; Elenitsas R; Taylor L; Lacey SF; Kulikovskaya I; Gupta M; Melenhorst JJ; Loren A; Frey N; June CH; Porter D; Rosenbach M
    J Am Acad Dermatol; 2016 Nov; 75(5):1054-1057. PubMed ID: 27745631
    [No Abstract]   [Full Text] [Related]  

  • 59. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
    Arakawa F; Shibaguchi H; Xu Z; Kuroki M
    Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.
    Textor A; Listopad JJ; Wührmann LL; Perez C; Kruschinski A; Chmielewski M; Abken H; Blankenstein T; Charo J
    Cancer Res; 2014 Dec; 74(23):6796-805. PubMed ID: 25297631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.